← All trials
NCT04664959
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 26, 2020
- Primary completion
- Sep 25, 2022
- Completion date
- Mar 26, 2023
- First posted
- Dec 11, 2020
- Last posted
- Dec 11, 2020
- Enrollment
- 432
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SamsungLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.